sayana press injectable contraceptive

Download Sayana press injectable contraceptive

Post on 12-Aug-2015

371 views

Category:

Health & Medicine

1 download

Embed Size (px)

TRANSCRIPT

  1. 1. A 12-month open-label randomized controlled trial to evaluate Sayana Press suitability for at home subcutaneous self-injection procedures in adult women Holly McClain Burke, PhD, MPH October 7, 2014
  2. 2. SAYANA PRESS 3-month contraceptive injectable 104 mg/0.65 mL of DMPA Prefilled Single dose, single package Non-reuseable Subcutaneous injection Compact size Easy to use Approved by EMA
  3. 3. Why is Sayana Press a game changer? Specifically developed to address logistics and safety challenges of widespread distribution in low-resource settings Potential for self-injection, which may: increase user autonomy and lower discontinuation rates decrease operational costs, improve efficient use of providers time, expand CHWs role reduce opportunity costs for users
  4. 4. FHI 360 PK Study Findings Injection of Depo-SubQ Provera 104 in the upper arm provided sufficient MPA levels for contraceptive protection for 3 months (13 weeks) Uptake and metabolism of MPA when injected in the upper arm may be different from the abdomen and thigh Important because 90% of client participants in the FHI 360 acceptability studies chose to receive Sayana Press in the upper arm
  5. 5. FHI 360 Acceptability Study Findings Acceptability studies in Uganda and Senegal completed in 2013 Most clients (80%) prefer Sayana Press over DMPA IM Most providers, including CHWs, preferred Sayana Press Sayana Press can be safely introduced into programs and administered by CHWs Providers spontaneously discussed self-injection After trying Sayana Press, 45% of clients in Uganda and 22% in Senegal would be willing to self-inject the method
  6. 6. Acceptability Study Research Objectives 1. Measure the acceptability of Sayana Press among family planning clients using DMPA IM 2. Measure the acceptability of Sayana Press among family planning providersboth clinic-based and community health workers (CHWs)
  7. 7. FHI 360 Acceptability Study Findings Acceptability studies in Uganda and Senegal completed in 2013 Most clients (80%) prefer Sayana Press over DMPA IM Most providers, including CHWs, preferred Sayana Press Sayana Press can be safely introduced into programs and administered by CHWs Providers spontaneously discussed self-injection After trying Sayana Press, 45% of clients in Uganda and 22% in Senegal would be willing to self-inject the method
  8. 8. Clients main reason for choosing Sayana Press Uganda n=98 Senegal n=192 Experienced no problems/fewer side effects 39 56 General statements about liking Sayana Press 39 37 No or less pain 8 20 Beneficial menstruation effects 8 6 Fast administration -- 30 Method effectiveness -- 18 Other 4 25
  9. 9. FHI 360 Acceptability Study Findings Acceptability studies in Uganda and Senegal completed in 2013 Most clients (80%) prefer Sayana Press over DMPA IM Almost all (98%) providers, including CHWs, preferred Sayana Press Sayana Press can be safely introduced into programs and administered by CHWs Providers spontaneously discussed self-injection After trying Sayana Press, 45% of clients in Uganda and 22% in Senegal would be willing to self-inject the method
  10. 10. Providers reasons for preferring Sayana Press
  11. 11. FHI 360 Acceptability Study Findings Acceptability studies in Uganda and Senegal completed in 2013 Most clients (80%) prefer Sayana Press over DMPA IM Most providers, including CHWs, preferred Sayana Press Sayana Press can be safely introduced into programs and administered by CHWs Providers spontaneously discussed self-injection After trying Sayana Press, 45% of clients in Uganda and 22% in Senegal would be willing to self-inject the method
  12. 12. Adverse Events (AEs) No pregnancies reported Total of 34 AEs reported by 25 clients One serious (malaria), but unrelated to SP 10 AEs possibly or definitely related to SP All mild or moderate in severity 3 AEs related to skin irritation at injection site 7 AEs are known side effects of DMPA
  13. 13. FHI 360 Acceptability Study Findings Acceptability studies in Uganda and Senegal completed in 2013 Most clients (80%) prefer Sayana Press over DMPA IM Most providers, including CHWs, preferred Sayana Press Sayana Press can be safely introduced into programs and administered by CHWs Providers spontaneously discussed self-injection After trying Sayana Press, 45% of clients in Uganda and 22% in Senegal would be willing to self-inject the method
  14. 14. HSI Study Setting: Malawi 33% of injectables users discontinue while still needing FP 6 MOH FP clinics in Mangochi District 20 clinic-based providers (i.e., nurses and/or midwives) 20 Health Surveillance Assistants (HSAs)
  15. 15. Primary Objective To compare continuation rates between women who self-inject Sayana Press compared to women who receive Sayana Press injection from a provider
  16. 16. Secondary Objectives Compare between the two groups: reported side effects pregnancy rates Describe experiences of women who self-inject Sayana Press Describe experiences and recommendations of family planning providers who train women to self-inject Sayana Press
  17. 17. Study Design Open-label randomized controlled trial Eligible women randomized to: 1. Receive Sayana Press from a provider, including HSAs, or 2. Receive training on how to self-inject Sayana Press and the opportunity to self-inject the method at home Participants will be followed for up to 1 year Interviews every 3 months shortly after re-injection date Measure: continuation status, acceptability, adverse events, experiences with side effects (including pain and injection site reactions), and pregnancy (at last interview only)
  18. 18. Eligibility Criteria INCLUSION: Age 18-40, inclusive In general good health Willing and able to give informed consent Willing to give contact information for follow-up Agree to have follow-up visits/interviews Willing to be randomized Meet eligibility criteria for receiving DMPA per WHO Medical Eligibility Criteria Menstrual period started within the past 7 days (for new DMPA users) EXCLUSION: Pregnancy Plans to become pregnant in the next 12 months Plans to relocate outside the study area in the next 12 months Any condition (social or medical) that would make study participation unsafe or would interfere with adherence to study
  19. 19. Enrollment Visit for Self-Injection Group Providers will train participants to self-inject Sayana Press Participants will self-inject Sayana Press under supervision Participants will be given 3 Sayana Press units to take home Community-Based Distribution Agents (CBDAs) will support self-injection in their communities
  20. 20. Additional Data Collection Track number of women who: were informed about the study, self-injected at enrollment, and self-injected on-time during year In-depth interviews with a small group of randomly selected self-injectors to understand strategies for remembering when to re-inject, fidelity to injection, storage and waste disposal procedures In-depth interviews with a small group of randomly selected providers to describe their techniques and recommendations for training and supporting women to self-inject
  21. 21. Project Timeline 2014 2015 2016 July Dec Jan March April - June July - Sept Oct - Dec Jan March April - June July - Sept Oct - Dec Study Start-Up X Enroll Participants X X Follow-up Visits X X X X X Conduct IDIs with providers X Conduct IDIs with self-injectors X Data Analysis X X X Dissemination X
  22. 22. Project Impact Inform decision-making for commodity procurement, placement, and distribution of Sayana Press Inform self-injection training materials, messages for providers and clients, and future scale-up efforts Sayana Press and self-injection may increase access to family planning and expand method mix at the primary and community levels